Last Updated: November 16, 2026

ZURAMPIC Drug Patent Profile

« Back to Dashboard


Which patents cover Zurampic, and what generic alternatives are available?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are eight patents protecting this drug.

The generic ingredient in ZURAMPIC is lesinurad. There is one drug master file entry for this compound. Additional details are available on the lesinurad profile page.

DrugPatentWatch® Generic Entry Outlook for Zurampic

Zurampic was eligible for patent challenges on December 22, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2028. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ZURAMPIC?
  • What are the global sales for ZURAMPIC?
  • What is Average Wholesale Price for ZURAMPIC?
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZURAMPIC
Generic Entry Date for ZURAMPIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZURAMPIC

ZURAMPIC is protected by eleven US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZURAMPIC is ⤷  Start Trial.

This potential generic entry date is based on patent 8,283,369.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 8,084,483 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 8,546,437 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 9,216,179 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 8,283,369 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ZURAMPIC

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Grünenthal GmbH Zurampic lesinurad EMEA/H/C/003932Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone., Withdrawn no no no 2016-02-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ZURAMPIC

When does loss-of-exclusivity occur for ZURAMPIC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 9753
Estimated Expiration: ⤷  Start Trial

Patent: 3548
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 08329673
Estimated Expiration: ⤷  Start Trial

Patent: 09289646
Estimated Expiration: ⤷  Start Trial

Patent: 09289647
Estimated Expiration: ⤷  Start Trial

Patent: 12203172
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 0819847
Estimated Expiration: ⤷  Start Trial

Patent: 0918584
Estimated Expiration: ⤷  Start Trial

Patent: 0918586
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 06858
Estimated Expiration: ⤷  Start Trial

Patent: 35828
Estimated Expiration: ⤷  Start Trial

Patent: 36117
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 08003529
Estimated Expiration: ⤷  Start Trial

Patent: 12000594
Estimated Expiration: ⤷  Start Trial

China

Patent: 1918377
Estimated Expiration: ⤷  Start Trial

Patent: 2186827
Estimated Expiration: ⤷  Start Trial

Patent: 2186832
Estimated Expiration: ⤷  Start Trial

Patent: 2643241
Estimated Expiration: ⤷  Start Trial

Patent: 3058944
Estimated Expiration: ⤷  Start Trial

Patent: 3819419
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 31333
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0140950
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 16286
Estimated Expiration: ⤷  Start Trial

Patent: 19010
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 17577
Estimated Expiration: ⤷  Start Trial

Ecuador

Patent: 10010310
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 8193
Estimated Expiration: ⤷  Start Trial

Patent: 3500
Estimated Expiration: ⤷  Start Trial

Patent: 1000897
Estimated Expiration: ⤷  Start Trial

Patent: 1100440
Estimated Expiration: ⤷  Start Trial

Patent: 1100441
Estimated Expiration: ⤷  Start Trial

Patent: 1270666
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 17577
Estimated Expiration: ⤷  Start Trial

Patent: 28874
Estimated Expiration: ⤷  Start Trial

Patent: 28879
Estimated Expiration: ⤷  Start Trial

Patent: 42948
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 60843
Estimated Expiration: ⤷  Start Trial

Patent: 72326
Estimated Expiration: ⤷  Start Trial

Patent: 80337
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 900009
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 5974
Estimated Expiration: ⤷  Start Trial

Patent: 1429
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 99794
Estimated Expiration: ⤷  Start Trial

Patent: 05934
Estimated Expiration: ⤷  Start Trial

Patent: 18327
Estimated Expiration: ⤷  Start Trial

Patent: 11504935
Estimated Expiration: ⤷  Start Trial

Patent: 12184234
Estimated Expiration: ⤷  Start Trial

Patent: 12502049
Estimated Expiration: ⤷  Start Trial

Patent: 12502050
Estimated Expiration: ⤷  Start Trial

Patent: 14196373
Estimated Expiration: ⤷  Start Trial

Patent: 15042647
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 2019003
Estimated Expiration: ⤷  Start Trial

Luxembourg

Patent: 0103
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 7370
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 10005776
Estimated Expiration: ⤷  Start Trial

Patent: 11002449
Estimated Expiration: ⤷  Start Trial

Patent: 11002450
Estimated Expiration: ⤷  Start Trial

Montenegro

Patent: 294
Estimated Expiration: ⤷  Start Trial

Patent: 996
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 936
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 5583
Patent: NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
Estimated Expiration: ⤷  Start Trial

Patent: 5035
Patent: Substituted diazole and triazole compounds and compositions and methods of use
Estimated Expiration: ⤷  Start Trial

Patent: 1774
Patent: Substituted diazole and triazole compounds and compositions and methods of use
Estimated Expiration: ⤷  Start Trial

Patent: 1786
Patent: Novel compounds and compositions and methods of use
Estimated Expiration: ⤷  Start Trial

Norway

Patent: 16016
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 17577
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 17577
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 569
Patent: NOVA JEDINJENJA I KOMPOZICIJE, TE POSTUPCI ZA UPOTREBU (NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE)
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 3721
Patent: NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 17577
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1003769
Patent: NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
Estimated Expiration: ⤷  Start Trial

Patent: 1101626
Patent: COMPOUNDS,COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS
Estimated Expiration: ⤷  Start Trial

Patent: 1203779
Patent: COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS
Estimated Expiration: ⤷  Start Trial

Patent: 1204031
Patent: COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1291643
Estimated Expiration: ⤷  Start Trial

Patent: 1294872
Estimated Expiration: ⤷  Start Trial

Patent: 1411806
Estimated Expiration: ⤷  Start Trial

Patent: 100085195
Estimated Expiration: ⤷  Start Trial

Patent: 110050708
Estimated Expiration: ⤷  Start Trial

Patent: 110050709
Estimated Expiration: ⤷  Start Trial

Patent: 120084787
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 13390
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 0927733
Patent: Novel compounds and compositions and methods of use
Estimated Expiration: ⤷  Start Trial

Patent: 1018463
Patent: Compounds, compositions and methods of using same for modulating uric acid levels
Estimated Expiration: ⤷  Start Trial

Patent: 1022216
Patent: Compounds, compositions and methods of using same for modulating uric acid levels
Estimated Expiration: ⤷  Start Trial

Patent: 77200
Estimated Expiration: ⤷  Start Trial

Patent: 15840
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 10000237
Patent: NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 2826
Patent: ПОХІДНІ ТРИАЗОЛУ ТА ЇХ ЗАСТОСУВАННЯ ЯК ЛІКАРСЬКОГО ЗАСОБУ (TRIAZOLE DERIVATIVES AND USE THEREOF AS A MEDICAMENT)
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZURAMPIC around the world.

Country Patent Number Title Estimated Expiration
Argentina 069753 ⤷  Start Trial
Argentina 073548 ⤷  Start Trial
Australia 2008329673 ⤷  Start Trial
Australia 2009289646 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZURAMPIC

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2135608 300825 Netherlands ⤷  Start Trial PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2135608 PA2016024 Lithuania ⤷  Start Trial PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2135608 93169 Luxembourg ⤷  Start Trial PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
2135608 CA 2016 00034 Denmark ⤷  Start Trial PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Zurampic Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 31, 2026

Zurampic, the brand name for lesinurad, has no active commercial trajectory in the United States. The FDA approved it in 2015 as an adjunct to a xanthine oxidase inhibitor for hyperuricemia associated with gout. AstraZeneca later transferred U.S. rights to Ironwood Pharmaceuticals, but Ironwood discontinued Zurampic and Duzallo in the United States after weak commercial performance. The product has no biosimilar pathway because lesinurad is a small-molecule drug, and no major generic competitor has established a meaningful U.S. market position.

What is Zurampic and how does it work?

Zurampic is an oral uric acid transporter 1 inhibitor containing lesinurad. It was approved for use with allopurinol or another xanthine oxidase inhibitor in patients who did not reach target serum uric acid levels with monotherapy.

Attribute Zurampic
Active ingredient Lesinurad
Drug class Selective uric acid reabsorption inhibitor
Initial U.S. sponsor AstraZeneca
Current U.S. commercial status Discontinued
FDA approval date Dec. 22, 2015
Approved use Adjunct treatment for hyperuricemia associated with gout
Dosage form 200 mg oral tablet once daily
Primary combination Allopurinol
Regulatory pathway New drug application
Biosimilar exposure None
Main competitive products Allopurinol, febuxostat, pegloticase, probenecid

The FDA label limited the dose to 200 mg once daily because higher doses increased renal and other safety risks. The label also warned against monotherapy because lesinurad was approved only in combination with a xanthine oxidase inhibitor.[1]

When did Zurampic lose commercial exclusivity?

Zurampic lost commercial viability before patent protection became the primary market issue. AstraZeneca discontinued U.S. commercialization and transferred rights to Ironwood, which later discontinued the product in the U.S. market.

U.S. commercial timeline

Date Event
2015 FDA approved Zurampic 200 mg tablets
2016 U.S. commercial launch
2016-2018 Limited uptake in the gout market
2017 FDA approved Duzallo, a fixed-dose lesinurad/allopurinol product
2018-2019 AstraZeneca transferred U.S. rights to Ironwood
2019-2020 Ironwood discontinued U.S. commercial operations for Zurampic and Duzallo
Current No meaningful branded U.S. sales platform

The product did not lose exclusivity through a high-volume generic launch. The principal loss mechanism was commercial withdrawal after limited demand, reimbursement friction, renal safety concerns, and the availability of established low-cost therapies.

What was Zurampic’s FDA regulatory status?

The FDA approved Zurampic under NDA 207988. The agency authorized the product as adjunctive therapy, not as standalone urate-lowering treatment.

The FDA label identified several risk-management requirements:

  • Baseline renal function assessment.
  • Periodic monitoring of serum creatinine.
  • Discontinuation or interruption for clinically important renal deterioration.
  • Use with a xanthine oxidase inhibitor.
  • Avoidance in severe renal impairment and end-stage renal disease.
  • Warnings concerning acute kidney injury and cardiovascular events.[1]

The regulatory profile constrained prescribing. Physicians had to add lesinurad to existing therapy rather than substitute it for allopurinol or febuxostat. That reduced the addressable market and increased treatment complexity.

What was the Orange Book status of Zurampic?

Zurampic was listed in the FDA Orange Book as a prescription drug product approved under an NDA. Orange Book patent listings are separate from current commercial availability. A product can remain associated with patent records even after the sponsor stops selling it.

The principal Orange Book-relevant questions are:

  1. Whether the listed patents remain unexpired.
  2. Whether the patents cover the active ingredient, formulation, method of use, or combination product.
  3. Whether any listed patent remains relevant to an ANDA applicant.
  4. Whether the reference product is commercially available for an ANDA applicant to rely on.

For Zurampic, the business significance of any residual patent term is limited by the absence of an active branded market. Patent protection can delay a generic launch, but it cannot create demand after the reference product has been withdrawn.

What patents protect lesinurad and Zurampic?

Lesinurad protection was based on a portfolio covering the chemical entity, pharmaceutical compositions, therapeutic use, and combination treatment with a xanthine oxidase inhibitor. The exact commercial value of each patent depended on claim scope, Orange Book listing status, patent-term adjustment, and any terminal disclaimer.

Main patent categories

Patent category Commercial purpose Risk profile
Active-ingredient patents Protect lesinurad as a chemical entity Usually strongest, but expiration is decisive
Composition patents Cover tablets, dosage forms, or pharmaceutical compositions Vulnerable to formulation-specific design-arounds
Method-of-use patents Cover treatment of hyperuricemia or gout Exposure depends on ANDA labeling and induced-infringement theories
Combination patents Cover lesinurad with allopurinol or another xanthine oxidase inhibitor Relevant to Duzallo and combination-use claims
Manufacturing patents Protect synthetic routes or intermediates Usually less important to ordinary generic substitution unless process claims are asserted

Publicly available patent information must be reviewed at the individual claim level. A patent number alone does not establish blocking power. The relevant analysis is whether an unexpired claim covers the proposed generic’s active ingredient, formulation, label, or manufacturing process.

No major public U.S. Paragraph IV litigation campaign generated a sustained generic challenge to Zurampic. Publicly visible patent disputes were limited compared with high-revenue products in oncology, immunology, diabetes, or rare disease.

Were there Paragraph IV challenges to Zurampic?

No major, commercially consequential Paragraph IV challenge is publicly associated with Zurampic. An ANDA applicant could have pursued one of several routes:

  • Paragraph IV certification against an unexpired Orange Book patent.
  • Paragraph III certification with launch after patent expiration.
  • A section viii statement omitting patented method-of-use information.
  • A generic lesinurad/allopurinol product with a label limited to non-patented indications.

The lack of a large Paragraph IV case reflects the product’s weak commercial economics. A generic company would have faced a small market, potential renal-safety liability, limited physician adoption, and competition from inexpensive allopurinol.

What happened to AstraZeneca’s Zurampic revenue?

Zurampic did not become a material AstraZeneca revenue driver. The company’s financial disclosures treated lesinurad-related revenue as commercially limited relative to its major respiratory, cardiovascular, oncology, and biologic franchises.

Financial trajectory

Period Financial direction Main driver
2015 Pre-commercial approval stage Regulatory launch preparation
2016 Initial revenue generation U.S. launch and limited uptake
2017 Modest expansion Duzallo approval and combination positioning
2018 Subscale performance Reimbursement and safety constraints
2019 Rights transfer and declining relevance AstraZeneca portfolio rationalization
2020 onward No meaningful U.S. branded trajectory Commercial discontinuation

AstraZeneca’s strategic decision to transfer the product reflected portfolio economics rather than a successful growth asset. Ironwood’s subsequent discontinuation confirmed that the product did not support a durable standalone sales infrastructure.

The revenue ceiling was constrained by several factors:

  • Allopurinol was generic and inexpensive.
  • Febuxostat provided an established alternative.
  • Gout treatment is often managed with titration of existing therapies.
  • Lesinurad required combination use.
  • Renal monitoring increased clinical friction.
  • The product carried a safety profile that limited broad prescribing.
  • Payers had limited incentive to reimburse a premium adjunctive therapy.

Which companies challenged or competed with Zurampic?

Zurampic competed against therapies rather than a single direct branded rival.

Competitive landscape

Product Company or market source Position relative to Zurampic
Allopurinol Generic manufacturers First-line, low-cost standard
Febuxostat Generic and branded suppliers Oral alternative to allopurinol
Probenecid Generic manufacturers Older uricosuric alternative
Krystexxa Horizon Therapeutics Injectable therapy for refractory chronic gout
Duzallo AstraZeneca, later Ironwood Fixed-dose lesinurad/allopurinol combination
Lesinurad generics No major established U.S. market Potential but commercially weak substitute

Allopurinol was the strongest competitive barrier. Zurampic had to demonstrate sufficient incremental value over a drug that is inexpensive, familiar, and widely used. A product that adds monitoring and safety restrictions must deliver clear clinical and economic benefits to displace that standard.

How did Zurampic compare with Duzallo?

Duzallo combined lesinurad and allopurinol in a single tablet. Its commercial rationale was convenience and adherence rather than a new pharmacologic mechanism.

Issue Zurampic Duzallo
Active ingredient Lesinurad Lesinurad plus allopurinol
Treatment model Add-on therapy Fixed-dose combination
FDA approval 2015 2017
Main commercial advantage Flexible combination use Reduced pill burden
Main commercial limitation Requires separate xanthine oxidase inhibitor Less dosing flexibility
U.S. outcome Discontinued Discontinued

Duzallo did not solve the core market problem. It improved convenience but retained lesinurad’s renal monitoring requirements, adjunctive positioning, payer barriers, and limited differentiation from inexpensive generic regimens.

What manufacturing and intellectual-property barriers affected lesinurad?

Lesinurad manufacturing required control of active pharmaceutical ingredient purity, polymorphic form, tablet formulation, and combination-product specifications. Those factors could support formulation or process patents, but they did not create a high barrier comparable with sterile injectables, biologics, or complex delivery systems.

The most relevant manufacturing risks were:

  • Scale-up consistency for the active ingredient.
  • Control of impurities and degradation products.
  • Bioequivalence for lesinurad tablets.
  • Fixed-dose combination equivalence for Duzallo.
  • Validation of dissolution and stability profiles.
  • Compliance with current good manufacturing practice requirements.

The product did not have biologic manufacturing complexity. It also had no biosimilar pathway, no device-dependent delivery system, and no cold-chain requirement. Those characteristics reduced technical barriers to generic development.

What generic entry risks exist for Zurampic?

Generic entry risk is commercially low but legally possible.

A prospective generic entrant would evaluate:

  1. Whether the FDA reference listed drug remains eligible for ANDA reliance.
  2. Whether Orange Book patents remain unexpired.
  3. Whether a Paragraph IV challenge is economically justified.
  4. Whether the proposed label can avoid patented method-of-use claims.
  5. Whether manufacturing scale can be supported by realistic demand.
  6. Whether wholesalers and payers would stock the product after branded withdrawal.

Even if a generic received FDA approval, the likely market would be narrow. A launch could target patients already receiving lesinurad, but the addressable population would be limited by discontinuation, physician switching, and the availability of alternative urate-lowering drugs.

What was the European regulatory status of Zurampic?

Lesinurad received European authorization as Zurampic and as combination therapy in Duzallo in the mid-2010s. The European product faced similar market constraints: adjunctive positioning, renal monitoring, limited differentiation, and competition from established urate-lowering therapies.

The European authorization was later withdrawn at the company’s request. The withdrawal was associated with commercial considerations rather than a broad regulatory finding that the active ingredient was ineffective for its approved use.[2]

What licensing deals affected Zurampic?

AstraZeneca’s transfer of U.S. rights to Ironwood was the most important commercial transaction involving Zurampic. The transaction moved responsibility for U.S. commercialization away from AstraZeneca and placed the products within Ironwood’s specialty-pharmaceutical portfolio.

The deal had strategic logic for both parties:

  • AstraZeneca could remove a subscale commercial asset.
  • Ironwood obtained a marketed gout product and a fixed-dose combination.
  • The transaction did not change the underlying clinical limitations.
  • Ironwood inherited a market requiring payer development and physician reeducation.

The subsequent discontinuation showed that licensing or rights transfer could not overcome the product’s weak demand profile.

What patent litigation affects Zurampic today?

No major active patent litigation has established Zurampic as a current U.S. litigation asset. The principal legal exposure is historical patent scope and any residual Orange Book effect on future ANDA development.

The absence of active litigation does not mean that all patents are irrelevant. It means the product has not generated the commercial incentives that typically produce repeated Paragraph IV filings, settlement agreements, launch-at-risk disputes, or extended patent litigation.

No major public settlement agreement has shaped current U.S. generic entry for Zurampic.

How strong is the Zurampic patent estate?

The estate was commercially moderate but strategically weak by the standards of high-value pharmaceutical products.

Strengths

  • Protection covered more than one technical category.
  • Combination and method-of-use claims supported the adjunctive treatment model.
  • Regulatory approval provided a defined reference product.
  • Lesinurad had a differentiated mechanism from xanthine oxidase inhibitors.

Weaknesses

  • The market was small.
  • Core treatment required combination use.
  • Generic allopurinol limited pricing power.
  • Method-of-use claims could be challenged through label design.
  • Formulation claims were potentially vulnerable to design-arounds.
  • Commercial withdrawal reduced the value of any remaining patent term.

Patent strength therefore did not translate into durable market power. The economic value of the estate was limited more by demand and product positioning than by an obvious absence of intellectual-property protection.

What is the outlook for Zurampic revenue and generic launch scenarios?

The base case is no meaningful branded revenue and limited generic activity.

Scenario Probability assessment Expected market effect
No U.S. reintroduction Highest Product remains commercially inactive
Single generic launch Low Small niche market, limited price realization
Multiple generic entrants Very low Requires a larger treated population than currently exists
New licensing deal Low Unlikely without a new commercial strategy
Repositioning in refractory gout Low Would require new clinical and reimbursement support
European re-entry Low Authorization and commercial barriers remain

A generic launch would be more plausible if a manufacturer targeted a retained-patient niche or used lesinurad in a broader specialty-gout portfolio. It would be less attractive as a standalone product.

Key Takeaways

  • Zurampic is lesinurad, an oral uricosuric approved in 2015 as add-on therapy to a xanthine oxidase inhibitor.
  • AstraZeneca transferred U.S. rights to Ironwood, which later discontinued Zurampic and Duzallo.
  • The product failed to achieve material commercial scale.
  • Allopurinol, febuxostat, and low-cost generic therapy limited pricing and adoption.
  • Renal monitoring and combination-use requirements restricted the addressable market.
  • No major Paragraph IV litigation or generic launch has defined the product’s U.S. lifecycle.
  • Zurampic has no biosimilar risk because it is a small molecule.
  • Residual patent rights have limited practical value without an active branded market.
  • The likely future is commercial inactivity rather than a competitive generic market.

FAQs

Is Zurampic still available in the United States?

No. Zurampic was discontinued from the U.S. commercial market after AstraZeneca transferred rights to Ironwood Pharmaceuticals.

Was Zurampic withdrawn because of safety problems?

The U.S. discontinuation was a commercial decision. The product label contained renal and cardiovascular warnings, but the commercial withdrawal was not a broad FDA safety withdrawal.

Can a generic company still launch lesinurad?

A generic company could pursue FDA approval if it satisfies applicable patent, regulatory, and bioequivalence requirements. The commercial opportunity is limited because the branded product is no longer actively marketed.

Is Duzallo still sold?

Duzallo, the fixed-dose lesinurad/allopurinol combination, was also discontinued in the United States.

What drug replaced Zurampic?

No single product replaced it. Physicians generally rely on allopurinol, febuxostat, probenecid, or pegloticase depending on disease severity, renal function, prior treatment, and patient response.

References

  1. U.S. Food and Drug Administration. (2019). Zurampic (lesinurad) tablets, prescribing information. FDA.

  2. European Medicines Agency. (2019). Zurampic: withdrawal of the marketing authorisation. EMA.

  3. AstraZeneca PLC. (2016-2019). Annual reports and Form 20-F filings. AstraZeneca.

  4. Ironwood Pharmaceuticals, Inc. (2019). Ironwood acquires U.S. rights to Zurampic and Duzallo. Ironwood Pharmaceuticals.

  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.